PUBLIC COMPANY
saveNeurotech Pharmaceuticals Inc
updated 23d ago
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
- phase3A Study to Determine the Safety and Efficacy of NT-501 With MHFM
- phase2Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
- phase2A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
- phase2A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
- phase2Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
- phase3A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
- phase3A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that